http://www.mmm-online.com/noah-pines/author/1449/ Latest articles by Noah Pines from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Physicians are renowned iPad enthusiasts, so your sales presentations have a lot to live up to. ­Fortunately, the ­latest generation of sales ­management platforms can take your tablet to a new level. Joe Dysart looks at three ­offerings http://www.mmm-online.com/closing-the-loop/article/294197/ Fri, 31 May 2013 04:00:00 GMT Physicians are renowned iPad enthusiasts, so your sales presentations have a lot to live up to. ­Fortunately, the ­latest generation of sales ­management platforms can take your tablet to a new level. Joe Dysart looks at three ­offerings MMM Science is yielding all-oral therapies that can cure hepatitis C in three months, without injected interferon. But there are potential headwinds. Noah Pines sorts out the leaders in hep. C and the rest of the pipeline http://www.mmm-online.com/therapeutic-focus-infectious-diseases/article/293793/ Fri, 31 May 2013 04:00:00 GMT Science is yielding all-oral therapies that can cure hepatitis C in three months, without injected interferon. But there are potential headwinds. Noah Pines sorts out the leaders in hep. C and the rest of the pipeline MMM Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from needle-based therapies http://www.mmm-online.com/therapeutic-focus-2013-rheumatology/article/290301/ Wed, 01 May 2013 04:00:00 GMT Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from needle-based therapies MMM As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how the new entrants are making inroads http://www.mmm-online.com/therapeutic-focus-2013-respiratory/article/286649/ Mon, 01 Apr 2013 04:00:00 GMT As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how the new entrants are making inroads MMM A relative's illness challenges a pharma consultant's view of industry progress. http://www.mmm-online.com/coming-face-to-face-with-advanced-cancer/article/285629/ Fri, 22 Mar 2013 16:07:42 GMT A relative's illness challenges a pharma consultant's view of industry progress. MMM The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at once. Noah Pines reports http://www.mmm-online.com/therapeutic-focus-2013-metabolic/article/281508/ Fri, 01 Mar 2013 05:00:00 GMT The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at once. Noah Pines reports MMM Companies are looking carefully at the rare disease area now. But there's a steep curve, as firms in this burgeoning space face a host of unique challenges http://www.mmm-online.com/therapeutic-focus-rare-diseases/article/277385/ Fri, 01 Feb 2013 05:00:00 GMT Companies are looking carefully at the rare disease area now. But there's a steep curve, as firms in this burgeoning space face a host of unique challenges MMM With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to growth, says Sanford Bernstein's Dr. Tim Anderson in a discussion with Noah Pines http://www.mmm-online.com/andersons-360-signs-of-life/article/269357/ Fri, 30 Nov 2012 05:00:00 GMT With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to growth, says Sanford Bernstein's Dr. Tim Anderson in a discussion with Noah Pines MMM Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment. http://www.mmm-online.com/bms-abbott-hcv-pill-data-suggest-competition-for-gilead/article/263850/ Tue, 16 Oct 2012 16:02:56 GMT Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment. MMM The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding. http://www.mmm-online.com/oped-meningitis-crisis-and-the-threat-to-pharma/article/263094/ Wed, 10 Oct 2012 19:06:58 GMT The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding. MMM